The promise of metabolic phenotyping in gastroenterology and hepatology

Nature Reviews Gastroenterology and Hepatology

Volumn 12, Issue 8, 2015, Pages 458-471

  Holmes, Elaine ^a   Wijeyesekera, Anisha ^a   Taylor Robinson, Simon D ^a   Nicholson, Jeremy K ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ALPHA INTERFERON; ARACHIDONIC ACID; BIOLOGICAL MARKER; CAPECITABINE; CREATININE; INTERLEUKIN 6; POLYPHENOL DERIVATIVE;

CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CAPILLARY ELECTROPHORESIS; CHEMOEMBOLIZATION; CLOSTRIDIUM DIFFICILE INFECTION; COLORECTAL CANCER; DYSBIOSIS; FECES MICROFLORA; FECES MICROFLORA TRANSPLANTATION; GASTROENTEROLOGY; GENOTYPE PHENOTYPE CORRELATION; HEPATITIS C; HEPATOLOGY; HUMAN; IMAGING SYSTEM; INFLAMMATORY BOWEL DISEASE; INTERNAL MEDICINE; INTESTINE FLORA; LIQUID CHROMATOGRAPHY; LIVER CANCER; LIVER RESECTION; LIVER TRANSPLANTATION; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLISM; METABOLITE; METABOLOMICS; MORPHOLOGICAL TRAIT; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE; PHARMACOGENETICS; PHENOTYPE; PHENOTYPIC PLASTICITY; PHENOTYPIC VARIATION; POPULATION GENETICS; PREVALENCE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; THERAPY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VIRUS HEPATITIS; BIOLOGICAL MODEL; GASTROINTESTINAL DISEASES; LIVER DISEASES; MEDICAL INFORMATICS; METABOLOME; MICROFLORA; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERSONALIZED MEDICINE; PHYSIOLOGY; PROCEDURES;

GASTROINTESTINAL DISEASES; HUMANS; LIVER DISEASES; MAGNETIC RESONANCE SPECTROSCOPY; MEDICAL INFORMATICS; METABOLOME; METABOLOMICS; MICROBIOTA; MODELS, BIOLOGICAL; PHENOTYPE; PRECISION MEDICINE;

EID: 84938738177     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2015.114     Document Type: Review

References (157)

1. Nicholson J. K. Global systems biology, personalized medicine and molecular epidemiology. Mol. Syst. Biol. 2, 52 (2006
2. Ogino S., et al. Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science. Am. J. Epidemiol. 176, 659-667 (2012
3. Kalow W. Pharmacogenetics and personalised medicine. Fundam. Clin. Pharmacol. 16, 337-342 (2002
4. Nicholson J. K., et al. Metabolic phenotyping in clinical and surgical environments. Nature 491, 384-392 (2012
5. Holmes E., Wilson I. D., & Nicholson J. K. Metabolic phenotyping in health and disease. Cell 134, 714-717 (2008
6. Hood L., Balling R., & Auffray C. Revolutionizing medicine in the 21st century through systems approaches. Biotechnol. J. 7, 992-1001 (2012
7. Pimiento J. M., et al. Melanoma genotypes and phenotypes get personal. Lab. Invest. 93, 858-867 (2013
8. Nicholson J. K., Holmes E., & Wilson I. D. Gut microorganisms, mammalian metabolism and personalized health care. Nat. Rev. Microbiol. 3, 431-438 (2005
9. Salazar N., et al. Inulin-type fructans modulate intestinal Bifidobacterium species populations and decrease fecal short-chain fatty acids in obese women. Clin. Nutr. 34, 501-507 (2014
10. Faith J. J., Ahern P. P., Ridaura V. K., Cheng J., & Gordon J. I. Identifying gut microbe-host phenotype relationships using combinatorial communities in gnotobiotic mice. Sci. Transl. Med. 6, 220ra11 (2014
11. Borgan E., et al. Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts. Mol. Oncol. 7, 130-142 (2013
12. Robinette S. L., Lindon J. C., & Nicholson J. K. Statistical spectroscopic tools for biomarker discovery and systems medicine. Anal. Chem. 85, 5297-5303 (2013
13. Ciccarelli O., et al. Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. Lancet Neurol. 13, 807-822 (2014
14. Woo J., Baumann A., & Arguello V. Recent advancements of flow cytometry: new applications in hematology and oncology. Expert Rev. Mol. Diagn. 14, 67-81 (2014
15. Wang Y. W., et al. Rapid ratiometric biomarker detection with topically applied SERS nanoparticles. Technology (Singap. World Sci.) 2, 118-132 (2014
16. Holmes E., et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 453, 396-400 (2008
17. Whiley L., et al. Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiol. Aging 35, 271-278 (2014
18. Maher A. D., et al. Optimization of human plasma 1H NMR spectroscopic data processing for high-throughput metabolic phenotyping studies and detection of insulin resistance related to type 2 diabetes. Anal. Chem. 80, 7354-7362 (2008
19. Hazen S. L. New lipid and lipoprotein targets for the treatment of cardiometabolic diseases. J. Lipid. Res. 53, 1719-1721 (2012
20. Cooper-Dehoff R. M., et al. Is diabetes mellitus-linked amino acid signature associated with β blocker induced impaired fasting glucose?. Circ. Cardiovasc. Genet. 7, 199-205 (2014
21. Shariff M. I., et al. Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation study. J. Proteome Res. 10, 1828-1836 (2011
22. Nicholson J. K., Everett J. R., & Lindon J. C. Longitudinal pharmacometabonomics for predicting patient responses to therapy: drug metabolism, toxicity and efficacy. Expert Opin. Drug Metab. Toxicol. 8, 135-139 (2012
23. Klootwijk E. D., et al. Mistargeting of peroxisomal EHHADH and inherited renal Fanconi's syndrome. N. Engl. J. Med. 370, 129-138 (2014
24. Pan Z., et al. Principal component analysis of urine metabolites detected by NMR and DESI-MS in patients with inborn errors of metabolism. Anal. Bioanal. Chem. 387, 539-549 (2007
25. Plumb R., et al. Ultra-performance liquid chromatography coupled to quadrupole-orthogonal time of flight mass spectrometry. Rapid Commun. Mass. Spectrom. 18, 2331-2337 (2004
26. Shockcor J. P., et al. Combined HPLC, NMR spectroscopy, and ion-trap mass spectrometry with application to the detection and characterization of xenobiotic and endogenous metabolites in human urine. Anal. Chem. 68, 4431-4435 (1996
27. Duarte I. F., Lamego I., Rocha C., & Gil A. M. NMR metabonomics for mammalian cell metabolism studies. Bioanalysis 1, 1597-1614 (2009
28. Jimenez B., et al. 1H HR MAS NMR spectroscopy of tumor-induced local metabolic field-effects enables colorectal cancer staging and prognostication. J. Proteome Res. 12, 959-968 (2013
29. Rocha C. M., et al. NMR metabolomics of human lung tumours reveals distinct metabolic signatures for adenocarcinoma and squamous cell carcinoma. Carcinogenesis 36, 68-75 (2014
30. Veselkov K. A., et al. Chemo-informatic strategy for imaging mass spectrometry-based hyperspectral profiling of lipid signatures in colorectal cancer. Proc. Natl Acad. Sci. USA 111, 1216-1221 (2014
31. Takats Z., Wiseman J. M., Gologan B., & Cooks R. G. Mass spectrometry sampling under ambient conditions with desorption electrospray ionization. Science 306, 471-473 (2004
32. Crecelius A. C., et al. Three-dimensional visualization of protein expression in mouse brain structures using imaging mass spectrometry. J. Am. Soc. Mass Spectrom. 16, 1093-1099 (2005
33. Balluff B., et al. De novo discovery of phenotypic intratumour heterogeneity using imaging mass spectrometry. J. Pathol. 235, 3-13 (2014
34. Veselkov K. A., et al. Recursive segment-wise peak alignment of biological 1H NMR spectra for improved metabolic biomarker recovery. Anal. Chem. 81, 56-66 (2009
35. Vu T. N., & Laukens K. Getting your peaks in line: a review of alignment methods for NMR spectral data. Metabolites 3, 259-276 (2013
36. Crutchfield C. A., et al. Comprehensive analysis of LC/MS data using pseudocolor plots. J. Am. Soc. Mass Spectrom. 24, 230-237 (2013
37. Trygg J., Holmes E., & Lundstedt T. Chemometrics in metabonomics. J. Proteome Res. 6, 469-479 (2007
38. Madsen R., Lundstedt T., & Trygg J. Chemometrics in metabolomics-a review in human disease diagnosis. Anal. Chim. Acta. 659, 23-33 (2010
39. Doeswijk T. G., Smilde A. K., Hageman J. A., Westerhuis J. A., & van Eeuwijk F. A. On the increase of predictive performance with high-level data fusion. Anal. Chim. Acta. 705, 41-47 (2011
40. Cloarec O., et al. Evaluation of the orthogonal projection on latent structure model limitations caused by chemical shift variability and improved visualization of biomarker changes in 1H NMR spectroscopic metabonomic studies. Anal. Chem. 77, 517-526 (2005
41. Posma J. M., Robinette S. L., Holmes E., & Nicholson J. K. MetaboNetworks, an interactive Matlab-based toolbox for creating, customizing and exploring sub-networks from KEGG. Bioinformatics 30, 893-895 (2014
42. Barupal D. K., et al. MetaMapp: mapping and visualizing metabolomic data by integrating information from biochemical pathways and chemical and mass spectral similarity. BMC Bioinformatics 13, 99 (2012
43. Trygg J., & Wold S. O2-PLS, a two-block (X Y) latent variable regression (LVR) method with an integral OSC filter. J. Chemom. 17, 53-64 (2003
44. Jayaseelan K. V., & Steinbeck C. Building blocks for automated elucidation of metabolites: natural product-likeness for candidate ranking. BMC bioinformatics 15, 234 (2014
45. Acar E., Lawaetz A. J., Rasmussen M. A., & Bro R. Structure-revealing data fusion model with applications in metabolomics. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2013, 6023-6026 (2013
46. Bro R., et al. Data fusion in metabolomic cancer diagnostics. Metabolomics 9, 3-8 (2013
47. Vaughan A. A., et al. Liquid chromatography-mass spectrometry calibration transfer and metabolomics data fusion. Anal. Chem. 84, 9848-9857 (2012
48. Cloarec O., et al. Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal. Chem. 77, 1282-1289 (2005
49. Keun H. C., et al. Heteronuclear 19F-1H statistical total correlation spectroscopy as a tool in drug metabolism: study of flucloxacillin biotransformation. Anal. Chem. 80, 1073-1079 (2008
50. Posma J. M., et al. Subset optimization by reference matching (STORM): an optimized statistical approach for recovery of metabolic biomarker structural information from 1H NMR spectra of biofluids. Anal. Chem. 84, 10694-10701 (2012
51. Shariff M. I., et al. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev. Gastroenterol. Hepatol. 3, 353-367 (2009
52. Wallace M. C., Preen D., Jeffrey G. P., & Adams L. A. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev. Gastroenterol. Hepatol. 9, 765-779 (2015
53. Duricova D., Burisch J., Jess T., Gower-Rousseau C., & Lakatos P. L. Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature. J. Crohns Colitis 8, 1351-1361 (2014
54. O'Keefe S. J., et al. Fat, fibre and cancer risk in African Americans and rural Africans. Nat. Commun. 6, 6342 (2015
55. Cho I., & Blaser M. J. The human microbiome: at the interface of health and disease. Nat. Rev. Genet. 13, 260-270 (2012
56. Dominguez-Bello M. G., Blaser M. J., Ley R. E., & Knight R. Development of the human gastrointestinal microbiota and insights from high-throughput sequencing. Gastroenterology 140, 1713-1719 (2011
57. Joyce S. A., & Gahan C. G. The gut microbiota and the metabolic health of the host. Curr. Opin. Gastroenterol. 30, 120-127 (2014
58. Nicholson J. K., et al. Host-gut microbiota metabolic interactions. Science 336, 1262-1267 (2012
59. Pande C., Kumar A., & Sarin S. K. Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. Aliment. Pharmacol. Ther. 29, 1273-1281 (2009
60. Vonlaufen A., Spahr L., Apte M. V., & Frossard J. L. Alcoholic pancreatitis: a tale of spirits and bacteria. World J. Gastrointest. Pathophysiol. 5, 82-90 (2014
61. Mehal W. Z. The gordian knot of dysbiosis, obesity and NAFLD. Nat. Rev. Gastroenterol. Hepatol. 10, 637-644 (2013
62. Swann J. R., et al. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc. Natl Acad. Sci. USA 108, 4523-4530 (2011
63. Claus S. P., et al. Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes. Mol. Syst. Biol. 4, 219 (2008
64. Tlaskalova-Hogenova H., et al. Microbiome and colorectal carcinoma: insights from germ-free and conventional animal models. Cancer J. 20, 217-224 (2014
65. Marcobal A., et al. A metabolomic view of how the human gut microbiota impacts the host metabolome using humanized and gnotobiotic mice. ISME J. 7, 1933-1943 (2013
66. Swann J., et al. Gut microbiome modulates the toxicity of hydrazine: a metabonomic study. Mol. Biosyst. 5, 351-355 (2009
67. Marchesi J. R., et al. Towards the human colorectal cancer microbiome. PLoS ONE 6, e20447 (2011
68. Magnusdottir S., Ravcheev D., De Crecy-Lagard V., & Thiele I. Systematic genome assessment of B vitamin biosynthesis suggests co-operation among gut microbes. Front. Genet. 6, 148 (2015
69. Raman M., et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 11, 868-875 (2013
70. Kelly C. R., et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am. J. Gastroenterol. 109, 1065-1071 (2014
71. Eiseman B., Silen W., Bascom G. S., & Kauvar A. J. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 44, 854-859 (1958
72. Gough E., Shaikh H., & Manges A. R. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin. Infect. Dis. 53, 994-1002 (2011
73. Weingarden A. R., et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am. J. Physiol. Gastrointest. Liver Physiol. 306, G310-G319 (2014
74. Borody T. J., Brandt L. J., & Paramsothy S. Therapeutic faecal microbiota transplantation: current status and future developments. Curr. Opin. Gastroenterol. 30, 97-105 (2014
75. Colman R. J., & Rubin D. T. Fecal microbiota transplantation as therapy for inflammatory bowel disease: A systematic review and meta-analysis. J. Crohns Colitis 8, 1569-1581 (2014
76. Hanauer S. B., & Sandborn W. Management of Crohn's disease in adults. Am. J. Gastroenterol. 96, 635-643 (2001
77. Seeley E. H., Washington M. K., Caprioli R. M., & M'Koma A. E. Proteomic patterns of colonic mucosal tissues delineate Crohn's colitis and ulcerative colitis. Proteomics Clin. Appl. 7, 541-549 (2013
78. Maus B., et al. Molecular reclassification of Crohn's disease: a cautionary note on population stratification. PLoS ONE 8, e77720 (2013
79. Gerich M. E., & McGovern D. P. Towards personalized care in IBD. Nat. Rev. Gastroenterol. Hepatol. 11, 287-299 (2014
80. Dawiskiba T., et al. Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases. World J. Gastroenterol. 20, 163-174 (2014
81. Williams H. R., et al. Serum metabolic profiling in inflammatory bowel disease. Dig. Dis. Sci. 57, 2157-2165 (2012
82. Fathi F., et al. 1H NMR based metabolic profiling in Crohn's disease by random forest methodology. Magn. Reson. Chem. 52, 370-376 (2014
83. Kostic A. D., Xavier R. J., & Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 146, 1489-1499 (2014
84. Sartor R. B. Microbial influences in inflammatory bowel diseases. Gastroenterology 134, 577-594 (2008
85. Elliott P., et al. Urinary metabolic signatures of human adiposity. Sci. Transl. Med. 7, 285ra62 (2015
86. Shaukat A., et al. Long-term mortality after screening for colorectal cancer. N. Engl. J. Med. 369, 1106-1114 (2013
87. Mirnezami R., et al. Chemical mapping of the colorectal cancer microenvironment via MALDI imaging mass spectrometry (MALDI-MSI) reveals novel cancer-associated field effects. Mol. Oncol. 8, 39-49 (2014
88. Chan E. C. Y., et al. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J. Proteome Res. 8, 352-361 (2009
89. Wang H., et al. 1H NMR-based metabolic profiling of human rectal cancer tissue. Mol. Cancer 12, 121 (2013
90. Zhu J., et al. Colorectal cancer detection using targeted serum metabolic profiling. J. Proteome Res. 13, 4120-4130 (2014
91. Montrose D. C., et al. Metabolic profiling, a noninvasive approach for the detection of experimental colorectal neoplasia. Cancer Prev. Res. 5, 1358-1367 (2012
92. Nishiumi S., et al. A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS ONE 7, e40459 (2012
93. Ibanez C., et al. CE/LC-MS multiplatform for broad metabolomic analysis of dietary polyphenols effect on colon cancer cells proliferation. Electrophoresis 33, 2328-2336 (2012
94. Tan B., et al. Metabonomics identifies serum metabolite markers of colorectal cancer. J. Proteome Res. 12, 3000-3009 (2013
95. Cross A. J., et al. A prospective study of serum metabolites and colorectal cancer risk. Cancer 120, 3049-3057 (2014
96. Silva C. L., Passos M., & Camara J. S. Investigation of urinary volatile organic metabolites as potential cancer biomarkers by solid-phase microextraction in combination with gas chromatography-mass spectrometry. Br. J. Cancer 105, 1894-1904 (2011
97. Eisner R., Greiner R., Tso V., Wang H., & Fedorak R. N. A machine-learned predictor of colonic polyps based on urinary metabolomics. BioMed Res. Int. 2013, 303982 (2013
98. Goedert J. J., et al. Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis 35, 2089-2096 (2014
99. Phua L. C., et al. Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol. Ther. 15, 389-397 (2014
100. Wedemeyer H., Dore G. J., & Ward J. W. Estimates on HCV disease burden worldwide -filling the gaps. J. Viral Hepat. 22 Suppl 1, 1-5 (2015
101. Trepo C., Chan H. L., & Lok A. Hepatitis B virus infection. Lancet 384, 2053-2063 (2014
102. Gomaa A. I., Khan S. A., Toledano M. B., Waked I., & Taylor-Robinson S. D. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J. Gastroenterol. 14, 4300-4308 (2008
103. Wiessing L., et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS ONE 9, e103345 (2014
104. Gomaa A. I., Hashim M. S., & Waked I. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in egypt. PLoS ONE 9, e90929 (2014
105. Kohli A., Shaffer A., Sherman A., & Kottilil S. Treatment of Hepatitis C: A systematic review. JAMA 312, 631-640 (2014
106. Ladep N. G., & Taylor-Robinson S. D. Management of liver disease in Nigeria. Clin. Med. 7, 439-441 (2007
107. Beyoglu D., & Idle J. R. The metabolomic window into hepatobiliary disease. J. Hepatol. 59, 842-858 (2013
108. Dumas M. E., Kinross J., & Nicholson J. K. Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease. Gastroenterology 146, 46-62 (2014
109. Cassol E., et al. Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect. Dis. 13, 203 (2013
110. Zhang A. H., Sun H., Han Y., Yan G. L., & Wang X. J. Urinary metabolic biomarker and pathway study of hepatitis B virus infected patients based on UPLC-MS system. PLoS ONE 8, e64381 (2013
111. Ladep N. G., et al. Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans. Hepatology 60, 1291-1301 (2014
112. Bosch F. X., Ribes J., Diaz M., & Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127, S5-S16 (2004
113. Patel M., et al. Hepatocellular carcinoma: diagnostics and screening. J. Eval. Clin. Pract. 18, 335-342 (2012
114. Johnson P. J. Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 14, S32-S36 (1999
115. Farinati F., et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: Both or neither?. Am. J. Gastroenterol. 101, 524-532 (2006
116. Bedossa P., & Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology 24, 289-293 (1996
117. Ishak K., et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 22, 696-699 (1995
118. Baranova A., Lal P., Birerdinc A., & Younossi Z. M. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol. 11, 91 (2011
119. Regev A., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am. J. Gastroenterol. 97, 2614-2618 (2002
120. De Groen P. C., Gores G. J., LaRusso N. F., Gunderson L. L., & Nagorney D. M. Biliary tract cancers. N. Engl. J. Med. 341, 1368-1378 (1999
121. Zabron A., Edwards R. J., & Khan S. A. The challenge of cholangiocarcinoma: Dissecting the molecular mechanisms of an insidious cancer. Dis. Model. Mech. 6, 281-292 (2013
122. Sithithaworn P., Yongvanit P., Duenngai K., Kiatsopit N., & Pairojkul C. Roles of liver fluke infection as risk factor for cholangiocarcinoma. J. Hepatobiliary Pancreat. Sci. 21, 301-308 (2014
123. Khan S. A., Thomas H. C., Davidson B. R., & Taylor-Robinson S. D. Cholangiocarcinoma. Lancet 366, 1303-1314 (2005
124. Shariff M. I., et al. Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population. J. Proteome Res. 9, 1096-1103 (2010
125. Canbakan B., et al. Clinical, biochemical and histological correlations in a group of non-drinker subjects with non-alcoholic fatty liver disease. Acta Gastroenterol. Belg. 70, 277-284 (2007
126. Dyson J. K., Anstee Q. M., & McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol. 5, 211-218 (2014
127. LaBrecque D. R., et al. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 48, 467-473 (2014
128. Corey K. E., & Kaplan L. M. Obesity and liver disease: The epidemic of the twenty-first century. Clin. Liver Dis. 18, 1-18 (2014
129. Gomaa A. I., Khan S. A., Leen E. L., Waked I., & Taylor-Robinson S. D. Diagnosis of hepatocellular carcinoma. World J. Gastroenterol. 15, 1301-1314 (2009
130. Barr J., et al. Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. J. Proteome Res. 9, 4501-4512 (2010
131. Barr J., et al. Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J. Proteome Res. 11, 2521-2532 (2012
132. Clayton T. A., Baker D., Lindon J. C., Everett J. R., & Nicholson J. K. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl Acad. Sci. USA 106, 14728-14733 (2009
133. Wang Z., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57-63 (2011
134. Yap I. K., et al. Metabolome-wide association study identifies multiple biomarkers that discriminate north and south Chinese populations at differing risks of cardiovascular disease: INTERMAP study. J. Proteome Res. 9, 6647-6654 (2010
135. Arteaga C. L., et al. Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat. Rev. Clin. Onc. 9, 16-32 (2012
136. Gutiu I. A., et al. Pharmacometabonomics, pharmacogenomics and personalized medicine. Rom. J. Intern. Med. 48, 187-191 (2010
137. Kwon H. N., et al. Predicting idiopathic toxicity of cisplatin by a pharmacometabonomic approach. Kidney Int. 79, 529-537 (2011
138. Nicholson J. K., Wilson I. D., & Lindon J. C. Pharmacometabonomics as an effector for personalized medicine. Pharmacogenomics 12, 103-111 (2011
139. Backshall A., Sharma R., Clarke S. J., & Keun H. C. Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. Clin. Cancer Res. 17, 3019-3028 (2011
140. Everett J. R., Loo R. L., & Pullen F. S. Pharmacometabonomics and personalized medicine. Ann. Clin. Biochem. 50, 523-545 (2013
141. K. C., et al. In vivo, in situ tissue analysis using rapid evaporative ionization mass spectrometry. Angew. Chem. Int. Ed. Engl. 48, 8240-8242 (2009
142. Balog J., et al. Intraoperative tissue identification using rapid evaporative ionization mass spectrometry. Sci. Transl. Med. 5, 194ra93 (2013
143. Strittmatter N., et al. Analysis of intact bacteria using rapid evaporative ionisation mass spectrometry. Chem. commun. 49, 6188-6190 (2013
144. Balog J., et al. Identification of biological tissues by rapid evaporative ionization mass spectrometry. Anal. Chem. 82, 7343-7350 (2010
145. Plichta J. K., et al. Does practice make perfect?. Resident experience with breast surgery influences excision adequacy. Am. J. Surg. 209, 547-551 (2015
146. Guenther S., et al. Spatially resolved metabolic phenotyping of breast cancer by desorption electrospray ionization mass spectrometry. Cancer Res. 75, 1828-1837 (2015
147. Nicholson J. K., & Lindon J. C. Systems biology: Metabonomics. Nature 455, 1054-1056 (2008
148. Lindon J. C., et al. Summary recommendations for standardization and reporting of metabolic analyses. Nat. Biotechnol. 23, 833-838 (2005
149. MRC-NIHR National Phenome Centre [online], http://www.imperial.ac.uk/phenomecentre/
150. Dona A. C., et al. Precision high-throughput proton NMR spectroscopy of human urine, serum, and plasma for large-scale metabolic phenotyping. Anal. Chem. 86, 9887-9894 (2014
151. Sarafian M. H., et al. Objective set of criteria for optimization of sample preparation procedures for ultra-high throughput untargeted blood plasma lipid profiling by ultra performance liquid chromatography-mass spectrometry. Anal. Chem. 86, 5766-5774 (2014
152. Human Metabolome Database [online], http://www.hmdb.ca
153. Mirnezami R., et al. Rapid diagnosis and staging of colorectal cancer via high-resolution magic angle spinning nuclear magnetic resonance (HR MAS NMR) spectroscopy of intact tissue biopsies. Ann. Surg. 259, 1138-1149 (2014
154. Cajka T., & Fiehn O. Comprehensive analysis of lipids in biological systems by liquid chromatography-mass spectrometry. Trends Analyt. Chem. 61, 192-206 (2014
155. Kurland I. J., et al. Application of combined omics platforms to accelerate biomedical discovery in diabesity. Ann. N. Y. Acad. Sci. 1287, 1-16 (2013
156. Nicholson J. K., Holmes E., Lindon J. C., & Wilson I. D. The challenges of modeling mammalian biocomplexity. Nat. Biotechnol. 22, 1268-1274 (2004
157. Biological Magnetic Resonance Data Bank [online], http://www.bmrb.wisc.edu